Efficacy of the PCSK9 inhibitors evolocumab/alirozumab in the reduction of LDL and Lp (a) in patients with familial hypercholesterolemia/manifest atherosclerosis in a real world setting
19 April 2018 (00:00 - 00:00)
Organised by:
About the speaker
University Clinic OWL, Bielefeld (Germany)
9 More presentations in this session
Doctor A. Chauca Tapia (Barcelona, ES)
Professor N. Mouine (Rabat, MA)
Access the full session
The Event
EuroPrevent 2018
19 April - 21 April 2018
